$FMS · Fresenius Medical Care AG
Fresenius Medical Care reported Q3 2026 results with revenue of EUR 4,937M (+1% reported, -1% constant currency) and a 19% drop in reported operating income to EUR 384M. Reported net income fell 42% to EUR 160M, largely due to EUR 108M in one-time costs from discontinuing the 4008A hemodialysis system and exiting peritoneal dialysis in China. FY2026 operating income guidance was narrowed to the lower half of the prior range — between flat and negative mid-single-digit percent growth.
- Q3 reported operating income fell 19% to EUR 384M, with margin compressing to 7.8% from 9.8% a year ago.
- Reported net income dropped 42% YoY to EUR 160M, driven by EUR 108M in one-time China strategy refinement costs.
- Adjusted EPS held flat at EUR 1.11 as share buybacks offset operating declines; 9.1M shares repurchased for EUR 357M.
- FY2026 operating income outlook narrowed to between flat and negative mid-single-digit percent growth — the lower half of prior range.
- U.S. same-market treatment growth turned negative at -1.1% in Q3; 9M figure at -0.8%.
Extended-hours trading shows FMS at $21.39, down 5.40% vs the regular close of $22.61, indicating the market is reacting negatively to the narrowed guidance and 42% reported net income drop. The $12.03B market cap stock is absorbing a guidance cut alongside significant China-related one-time charges.
A guidance cut to the lower half of the range, a 42% net income drop, and a new CEO three weeks into the role combine to signal a turnaround story under pressure.
The dialysis duopoly (Fresenius and DaVita) faces persistent TDAPA drug reimbursement pressure in the U.S. Fresenius's 5008X CAREsystem rollout (16% of U.S. clinics converted) and multiFiltratePRO launch represent product-cycle catalysts, but near-term earnings are being absorbed by restructuring and inflation.
China strategy refinement triggered EUR 108M in one-time costs (impairments, scrappage, termination) from discontinuing the 4008A hemodialysis system and exiting peritoneal dialysis. TDAPA reimbursement headwinds and accelerated inflationary cost increases continue to pressure margins. U.S. same-market treatment growth is now negative.